Chronic Myelogenous Leukemia | Disease | Continental Hospitals
For Appointments
040 6700 0000
Emergency
040 6700 0111

Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the abnormal growth of white blood cells, specifically the myeloid cells. This condition is caused by a genetic mutation known as the Philadelphia chromosome, which leads to uncontrolled cell division. CML typically progresses slowly, with three distinct phases: chronic phase, accelerated phase, and blast crisis. 

symptoms of Chronic Myelogenous Leukemia

If you suspect you or someone else is experiencing Chronic Myelogenous Leukemia, it is crucial to seek immediate medical attention by calling emergency services or consult with a Cancer Specialist.

Causes of Chronic Myelogenous Leukemia (CML)

  • Genetic Mutation (Philadelphia Chromosome): The most common cause of CML is the formation of the Philadelphia chromosome, a genetic abnormality where parts of chromosomes 9 and 22 swap places. This results in the production of the BCR-ABL fusion gene, which triggers uncontrolled cell division.

  • Exposure to Ionizing Radiation: High levels of radiation exposure, such as from nuclear accidents or cancer treatments, increase the risk of developing CML.

  • Chemotherapy Drugs: Certain chemotherapy drugs used for other types of cancer can increase the likelihood of developing secondary leukemias, including CML.

  • Environmental Toxins: Long-term exposure to chemicals like benzene, which is found in industrial solvents and tobacco smoke, may increase the risk of CML.

  • Age and Gender: CML is more commonly diagnosed in adults, especially those over the age of 60. It also tends to be more prevalent in men.

  • Family History: While rare, having a family member with CML or other blood cancers may slightly increase the risk of developing the disease.

  • Immune System Disorders: Certain autoimmune conditions or other blood disorders can predispose individuals to leukemia, though this is not a primary cause.

Risk Factors of Chronic Myelogenous Leukemia (CML)

  • Age: Most common in adults aged 55-60.
  • Gender: Slightly more common in men than women.
  • Radiation Exposure: Previous exposure to high levels of radiation (e.g., radiation therapy for other cancers).
  • Family History: A small risk if there is a family history of leukemia.
  • Genetic Mutations: Presence of the Philadelphia chromosome (BCR-ABL gene fusion).
  • Chemotherapy History: Previous treatment with certain chemotherapy drugs may increase risk.
  • Environmental Factors: Exposure to certain chemicals or toxins, such as benzene, may contribute to risk.

Symptoms of Chronic Myelogenous Leukemia (CML)

  • Fatigue: Feeling unusually tired or weak, even with adequate rest.

  • Weight Loss: Unexplained weight loss without changes in diet or exercise.

  • Night Sweats: Excessive sweating, particularly at night, that can soak clothes or sheets.

  • Fever: Low-grade fever that persists or comes and goes.

  • Pain or Fullness Below the Ribs: Enlarged spleen (splenomegaly) or liver (hepatomegaly), which can cause discomfort, pain, or a sense of fullness in the abdomen.

  • Pale Skin: A pale complexion, often due to anemia (low red blood cell count).

  • Frequent Infections: Increased susceptibility to infections due to a weakened immune system.

  • Easy Bruising or Bleeding: Unexplained bruising, prolonged bleeding, or frequent nosebleeds.

  • Bone or Joint Pain: Discomfort or pain in the bones or joints.

  • Abdominal Discomfort: Feeling full or bloated due to spleen or liver enlargement.

  • Shortness of Breath: Difficulty breathing, especially during physical activity, due to anemia or spleen enlargement.

Need an Appointment?

Diagnosis for Chronic Myelogenous Leukemia (CML)

  • Blood Tests: A complete blood count (CBC) can reveal elevated white blood cell levels, a hallmark of CML. The presence of abnormal cells may also be detected.

  • Bone Marrow Biopsy: A sample of bone marrow is taken from the hipbone or another site to look for characteristic abnormalities, including increased numbers of immature white blood cells.

  • Philadelphia Chromosome Test: The most definitive test for CML, this involves detecting the genetic abnormality that leads to the Philadelphia chromosome. This can be done via:

    • Fluorescence in situ hybridization (FISH): A technique to visualize the Philadelphia chromosome and confirm the presence of the BCR-ABL fusion gene.
    • Polymerase Chain Reaction (PCR): A highly sensitive test to detect the BCR-ABL gene at a molecular level.

  • Cytogenetic Analysis: A test that looks at the chromosomes of the leukemia cells to identify the Philadelphia chromosome or other genetic changes.

  • Imaging Tests: Imaging studies like ultrasound or CT scans may be used to check for spleen or liver enlargement, which can be associated with CML.

  • Physical Examination: A doctor may check for signs like an enlarged spleen or liver, or look for other physical symptoms such as bruising or pallor.

  • Genetic and Molecular Profiling: To assess the presence of specific mutations in the BCR-ABL gene that may affect treatment decisions.

Treatments for Chronic Myelogenous Leukemia (CML)

  • Tyrosine Kinase Inhibitors (TKIs): The primary treatment for CML, these drugs target the BCR-ABL fusion protein caused by the Philadelphia chromosome. Common TKIs include:

    • Imatinib (Gleevec)
    • Dasatinib (Sprycel)
    • Nilotinib (Tasigna)
    • Bosutinib (Bosulif)
    • Ponatinib (Iclusig), used in cases with specific mutations.

  • Stem Cell Transplant (Allogeneic Hematopoietic Stem Cell Transplant): A potential treatment for patients who do not respond to TKIs or those who progress to the accelerated or blast phase of CML. It involves replacing the patient's diseased bone marrow with healthy stem cells from a donor.

  • Chemotherapy: Used less commonly today, chemotherapy may be given in certain cases, particularly if the disease progresses to a more advanced phase.

  • Interferon Therapy: Older treatment that may still be used in specific cases, especially for patients who cannot tolerate TKIs.

  • Targeted Therapy: In addition to TKIs, other molecular targeted treatments may be used based on genetic mutations or resistance to standard TKIs.

  • Supportive Care: Includes treatments to manage symptoms and side effects, such as:

    • Blood transfusions for anemia or low red blood cells.
    • Antibiotics for infections due to weakened immunity.
    • Pain management for bone or joint pain.

  • Regular Monitoring: Continuous monitoring through blood tests and PCR to assess the effectiveness of treatment and detect potential resistance to therapy.

Preventive Measures for Chronic Myelogenous Leukemia (CML)

  • Limit Exposure to Ionizing Radiation: Avoid unnecessary radiation exposure, such as frequent X-rays or radiation therapy, unless medically required.

  • Minimize Exposure to Environmental Toxins: Reduce exposure to harmful chemicals like benzene, which is found in industrial solvents and tobacco smoke. Occupational safety measures should be followed in workplaces dealing with such chemicals.

  • Avoid Smoking: Smoking has been linked to an increased risk of various cancers, including leukemia. Quitting smoking can lower this risk.

  • Use Protective Measures in Occupational Settings: For individuals working in environments with hazardous chemicals, wearing appropriate protective gear and following safety guidelines can minimize exposure to potential carcinogens.

  • Healthy Diet and Exercise: While not directly preventing CML, maintaining a healthy lifestyle through a balanced diet and regular physical activity can boost the immune system and reduce the risk of overall health issues, including certain cancers.

  • Regular Medical Check-ups: Routine health check-ups and screenings can help identify early signs of any potential health issues, although CML is not typically detected through general screenings.

Do's & Don’t's

When it comes to managing Chronic Myelogenous Leukemia (CML), there are certain do's and don'ts that patients should be aware of. By following these guidelines, individuals can better navigate their treatment journey and improve their overall well-being. 

Do's Don't
Follow your healthcare team's treatment plan Don't skip medications without consulting your healthcare team
Attend regular medical check-ups and follow-up appointments Avoid self-diagnosis and self-treatment; always consult your healthcare provider
Communicate openly with your healthcare team about any concerns or side effects Don't ignore symptoms or side effects; report them promptly to your healthcare team
Maintain a healthy and balanced diet, including fruits, vegetables, lean proteins, and whole grains Avoid extreme diets or dietary supplements without consulting your healthcare team
Stay physically active within the limits recommended by your healthcare team Don't engage in strenuous activities without approval from your healthcare provider
Get adequate rest and prioritize good sleep hygiene Avoid excessive alcohol consumption and tobacco use
Practice good hygiene to reduce the risk of infections Avoid close contact with individuals who have contagious illnesses
Stay well-hydrated Don't neglect your mental health; seek support if needed, and inform your healthcare team about any emotional challenges
Monitor and manage stress through relaxation techniques and activities Don't delay in reporting any unusual or worsening symptoms to your healthcare team
Stay informed about CML and its treatment options Avoid alternative therapies without discussing them with your healthcare team

If you suspect you or someone else is experiencing Chronic Myelogenous Leukemia, it is crucial to seek immediate medical attention by calling emergency services or consult with a Cancer Specialist.

Frequently Asked Questions
Chronic Myelogenous Leukemia (CML) is a type of cancer that affects the blood and bone marrow. It is characterized by the abnormal growth of white blood cells, specifically the myeloid cells. This condition is caused by a genetic mutation known as the Philadelphia chromosome, which leads to uncontrolled cell division.
One of the common causes associated with CML is a genetic abnormality known as the Philadelphia chromosome, which occurs when there is an exchange of genetic material between chromosomes 9 and 22. This abnormality leads to the production of an abnormal protein called BCR-ABL1, which plays a critical role in the development of CML.
Several factors contribute to the development of CML. One significant risk factor is exposure to high levels of radiation, such as previous radiation therapy or nuclear accidents. Additionally, certain genetic mutations, particularly the presence of the Philadelphia chromosome (a specific abnormality in chromosomes), are strongly linked to the onset of CML.
One of the common symptoms of CML is fatigue or weakness, which may be persistent and unexplained. Patients may also experience unexplained weight loss, night sweats, or fever without any apparent cause. Additionally, CML can lead to an enlarged spleen, causing discomfort or pain in the left upper abdomen.
One of the primary diagnostic tools used for CML is a blood test called a complete blood count (CBC). This test helps in evaluating the number and types of cells in the blood, including white blood cells, red blood cells, and platelets. Abnormalities in these cell counts can indicate the presence of CML.
One of the most common approaches to treating CML is targeted therapy. This involves using medications that specifically target cancer cells while sparing healthy cells. The development of tyrosine kinase inhibitors (TKIs) has revolutionized CML treatment. TKIs work by blocking the activity of abnormal proteins that promote the growth of cancer cells.
One of the primary prevention strategies for CML is to avoid exposure to certain risk factors. For instance, limiting exposure to ionizing radiation, such as medical imaging procedures and nuclear accidents, can help minimize the risk. Additionally, reducing exposure to certain chemicals and toxins, such as benzene and formaldehyde, which are known carcinogens, may also be beneficial.